• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

InspireMD touts 2-year CGuard EPS results
InspireMD (NYSE:NSPR) this week released two-year results from the Paradigm 101 clinical study of its CGuard embolic protection system. Results from the trial were initially presented at the 2017 VEITH Symposium in New York last month. In the investigator-led study, researchers examined the use of the CGuard EPS system in 101 patients with symptomatic or high-risk asymptomatic carotid artery stenosis. Data from the study indicated that there were no deaths, major stroke or myocardial infarctions as a result of periprocedural or postprocedural interventions at at two years. InspireMD said that the results were consistent w...
Source: Mass Device - December 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Neurological InspireMD Source Type: news